Manuel Santiago García Velosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Manuel Santiago García Velosa has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Hurtado-Ortiz
Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia; Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia
1 shared publication - Betsabé Patricia Vizcaino Cevallos
Universidad San Francisco de Quito USFQ
1 shared publication - Carlos Augusto Solórzano-Ramos
Hospital Internacional de Colombia HIC-Fundación Cardiovascular de Colombia FCV, Km 7 Autopista Bucaramanga—Piedecuesta Valle de Mensulí, Piedecuesta 680001, Colombia
1 shared publication - Celine Lucero Ludwig Hernández1 shared publication
- Edgar Fabián Manrique-Hernández
Epidemiología Clínica, Hospital Internacional de Colombia HIC- Fundación Cardiovascular de Colombia FCV- Fundación Universitaria FCV, Piedecuesta, Santander, Colombia
1 shared publication - Erika Romina Cuenca Riascos
Universidad Estatal de Bolívar, Ecuador
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 5 (2)
Beyond Hemostasis: Integrated Anticoagulation Reversal, Hemodynamic Optimization, and Neurosurgical Decision-Making in Intracerebral Hemorrhage
Anticoagulant-associated intracerebral hemorrhage represents a life-threatening neurological emergency characterized by rapid hematoma expansion, secondary cerebral injury, and substantial risks of mortality and long-term functional disability. Its management requires coordinated therapeutic strategies addressing anticoagulant activity, systemic hemodynamics, and intracranial complications. This narrative review critically examines current international evidence regarding pharmacological reversal, blood pressure management, and neurosurgical intervention, incorporating perspectives relevant to Latin American healthcare systems. Twenty scientific publications, including randomized controlled trials, observational investigations, and clinical guidelines, were analyzed through a comparative qualitative approach. Evidence from the INCH trial demonstrated more rapid normalization of coagulation parameters with four-factor prothrombin complex concentrate than with fresh frozen plasma. ANNEXA-I reported greater hemostatic efficacy with andexanet alfa compared with usual care, although thrombotic complications were more frequent and functional benefits were not established. Findings from INTERACT2 and ATACH-II highlighted differences in clinical outcomes associated with intensive blood pressure reduction, whereas INTERACT3 demonstrated improved functional outcomes through coordinated management of physiological abnormalities. Neurosurgical evidence from MISTIE III and ENRICH revealed that the effectiveness of minimally invasive hematoma evacuation depends on procedural technique, anatomical characteristics, treatment timing, and patient selection. Across the reviewed studies, improvements in hemostatic or radiological parameters did not consistently translate into reduced mortality or sustained neurological recovery. The findings support an individualized, multidisciplinary approach integrating prompt anticoagulant reversal, controlled hemodynamic stabilization, continuous neurological assessment, and selective neurosurgical treatment. Further investigations are needed to establish optimal therapeutic sequencing, anticoagulant-specific surgical criteria, and implementation strategies adapted to resource-variable healthcare environments.
- 30 June 2026
- Published by Quality Consulting Instituto de Educación Capacitación y Certificación de México in IECCMEXICO
- Vol. 5 (2)
Open AccessBeyond Hemostasis: Integrated Anticoagulation Reversal, Hemodynamic Optimization, and Neurosurgical Decision-Making in Intracerebral Hemorrhage
Anticoagulant-associated intracerebral hemorrhage represents a life-threatening neurological emergency characterized by rapid hematoma expansion, secondary cerebral injury, and substantial risks of mortality and long-term functional disability. Its management requires coordinated therapeutic strategies addressing anticoagulant activity, systemic hemodynamics, and intracranial complications. This narrative review critically examines current international evidence regarding pharmacological reversal, blood pressure management, and neurosurgical intervention, incorporating perspectives relevant to Latin American healthcare systems. Twenty scientific publications, including randomized controlled trials, observational investigations, and clinical guidelines, were analyzed through a comparative qualitative approach. Evidence from the INCH trial demonstrated more rapid normalization of coagulation parameters with four-factor prothrombin complex concentrate than with fresh frozen plasma. ANNEXA-I reported greater hemostatic efficacy with andexanet alfa compared with usual care, although thrombotic complications were more frequent and functional benefits were not established. Findings from INTERACT2 and ATACH-II highlighted differences in clinical outcomes associated with intensive blood pressure reduction, whereas INTERACT3 demonstrated improved functional outcomes through coordinated management of physiological abnormalities. Neurosurgical evidence from MISTIE III and ENRICH revealed that the effectiveness of minimally invasive hematoma evacuation depends on procedural technique, anatomical characteristics, treatment timing, and patient selection. Across the reviewed studies, improvements in hemostatic or radiological parameters did not consistently translate into reduced mortality or sustained neurological recovery. The findings support an individualized, multidisciplinary approach integrating prompt anticoagulant reversal, controlled hemodynamic stabilization, continuous neurological assessment, and selective neurosurgical treatment. Further investigations are needed to establish optimal therapeutic sequencing, anticoagulant-specific surgical criteria, and implementation strategies adapted to resource-variable healthcare environments.
- 15 June 2026
- Published by Asociacion Colombiana de Infectologia - ACIN in Infectio
- p. 128-135
Microbial and Clinical Characteristics in Hepatobiliary Surgery Patients: Analyzing Risk Factors and Antibiotic Resistance
Introduction: Bactibilia frequently complicates biliary obstruction, especially in malignant cases with drainage, and is associated with antimicrobial resistance, thereby posing significant therapeutic challenges. This study characterized the microbiological and clinical profiles, antibiotic resistance patterns, and associated risk factors in patients undergoing hepatobiliary surgery in Colombia. Materials and Methods: We conducted a cross-sectional analytical study on 95 patients with positive bacterial cultures following surgery. The analysis included clinical and microbiological variables. For analytical purposes, patients were stratified into two groups: those with PBD and those without, allowing for the assessment of clinical and microbiological differences between the cohorts. We used chi-square tests, Student’s t-tests, Mann–Whitney tests, and logistic regression. Results: Of the 95 patients, 61.05% were men, with a median age of 67 years. Preoperative exposure to endoscopic retrograde cholangiopancreatography was significantly higher in patients with biliary pancreatitis (73.47%; p=0.001). Escherichia coli exhibited high resistance to ampicillin/sulbactam (74.29%) and ciprofloxacin (59.46%), while piperacillin/tazobactam (89.74%). Resistance to meropenem was notably associated with female sex (odds ratio [OR: 9.55; 95% confidence Interval [CI], 1.12–80.9; P=0.038) and longer ICU stay (OR: 1.12; 95% CI, 1.00–1.24; P=0.038). Discussion: This study reveals significant antibiotic resistance in E. coli and K. pneumoniae, especially in patients with preoperative biliary drainage. These findings highlight the importance of tailoring antibiotic prophylaxis based on preoperative cultures to effectively address antibiotic resistance in hepatobiliary surgery.
- 15 June 2026
- Published by Asociacion Colombiana de Infectologia - ACIN in Infectio
- p. 128-135
Microbial and Clinical Characteristics in Hepatobiliary Surgery Patients: Analyzing Risk Factors and Antibiotic Resistance
Introduction: Bactibilia frequently complicates biliary obstruction, especially in malignant cases with drainage, and is associated with antimicrobial resistance, thereby posing significant therapeutic challenges. This study characterized the microbiological and clinical profiles, antibiotic resistance patterns, and associated risk factors in patients undergoing hepatobiliary surgery in Colombia. Materials and Methods: We conducted a cross-sectional analytical study on 95 patients with positive bacterial cultures following surgery. The analysis included clinical and microbiological variables. For analytical purposes, patients were stratified into two groups: those with PBD and those without, allowing for the assessment of clinical and microbiological differences between the cohorts. We used chi-square tests, Student’s t-tests, Mann–Whitney tests, and logistic regression. Results: Of the 95 patients, 61.05% were men, with a median age of 67 years. Preoperative exposure to endoscopic retrograde cholangiopancreatography was significantly higher in patients with biliary pancreatitis (73.47%; p=0.001). Escherichia coli exhibited high resistance to ampicillin/sulbactam (74.29%) and ciprofloxacin (59.46%), while piperacillin/tazobactam (89.74%). Resistance to meropenem was notably associated with female sex (odds ratio [OR: 9.55; 95% confidence Interval [CI], 1.12–80.9; P=0.038) and longer ICU stay (OR: 1.12; 95% CI, 1.00–1.24; P=0.038). Discussion: This study reveals significant antibiotic resistance in E. coli and K. pneumoniae, especially in patients with preoperative biliary drainage. These findings highlight the importance of tailoring antibiotic prophylaxis based on preoperative cultures to effectively address antibiotic resistance in hepatobiliary surgery.